Author: David MageePublisher:
ISBN:
Category :
Languages : en
Pages :
Book Description
Background Advances in cancer therapies have led to an increase in the cancer survivors. Chemotherapy-induced peripheral neuropathy (CIPN) can cause significant persistent pain and disability in this population. Evidence for effective management for CIPN is lacking. Pharmacotherapy options include anti-neuropathic agents and/ or topical therapies. We provided a descriptive analysis of the change in different outcome measures in patients with CIPN treated at the Royal Marsden Hospital (RMH).MethodPatients with CIPN attending RMH Pain Clinics between January 2106 and December 2018, who consented to providing data through a bespoke tablet interface (Research Ethics Committee approved) were divided into three treatment groups; anti-neuropathics only, topicals only or combined therapy. Those who did not complete a repeat attendance questionnaire were excluded. Average change in outcome measures [Brief Pain Inventory (Symptom severity; SS and Interference severity; IS) and Hospital Anxiety and Depression Score; HADS] before and after treatment were analyzed. Patient Satisfaction Scores (%) were also measured.ResultsEighty-one CIPN patients were included. Of these, 43 patients completed repeat attendance questionnaires. Thirty were treated with combined anti-neuropathic and topical agents, 4 with anti-neuropathics only and 9 with topicals only. The greatest outcome change was seen in anti-neuropathic treatment group; SS (1.6), IS (1.6) and in topical treatment group for HADS (2.4).ConclusionThe average reduction in SS and IS scores are greatest in the anti-neuropathic only group. The highest improvement in HADS is in the topicals only group. The smaller number of patients in anti-neuropathic only group may account for difference in changes. Overall, there was high patient satisfaction in all groups.